/NEUP
NEUP Stock - Neuphoria Therapeutics Inc.
Healthcare|Medical - PharmaceuticalsNASDAQ
$3.89+0.00%
+$0.00 (+0.00%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+79.9%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NEUP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.85 – $3.93
TARGET (TP)$7.00
STOP LOSS$3.58
RISK/REWARD1:10.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$21.40
52W Low$2.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $23.95M | N/A | N/A | $277,892.5 | N/A |
| Gross Profit | $22.94M | $-992,563 | $-671,419 | N/A | $-1,691,056 |
| Gross Margin | 95.8% | N/A | N/A | 0.0% | N/A |
| Operating Income | $-1,728,231 | $-26,786,676 | $-22,255,712 | $-28,600,707 | $-12,946,664 |
| Net Income | $-565,773 | $-23,193,321 | $-21,646,954 | $-22,936,204 | $-8,646,819 |
| Net Margin | -2.4% | N/A | N/A | -8253.6% | N/A |
| EPS | $-0.23 | $-0.10 | $-0.17 | $-0.13 | $-0.10 |
Company Overview
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NEUPBeat Rate
44%
Last 9 quarters
Avg Surprise
-26.3%
EPS vs Estimate
Beats / Misses
4/5
Last 12 quarters
Latest EPS
$-4.41
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
-156.2%
$-29.16vs$-11.38
Q4 24
No data
Q1 25
+99.6%
$-0.01vs$-2.01
Q2 25
+1493.6%
$6.55vs$-0.47
Q3 25
-933.9%
$-5.79vs$-0.56
Q4 25
-701.8%
$-4.41vs$-0.55
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 13, 2026 | $-0.56 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.55 | $-4.41 | -701.8% | ✗ MISS |
Q3 2025 | Sep 29, 2025 | $-0.56 | $-5.79 | -933.9% | ✗ MISS |
Q2 2025 | May 20, 2025 | $-0.47 | $6.55 | +1493.6% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-2.01 | $-0.01 | +99.6% | ✓ BEAT |
Q4 2024 | Nov 15, 2024 | — | $-0.00 | — | — |
Q3 2024 | Sep 30, 2024 | $-11.38 | $-29.16 | -156.2% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-0.02 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.03 | — | — |
Q3 2023 | Sep 30, 2023 | $-13.44 | $-0.01 | +100.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-15.30 | $-17.65 | -15.3% | ✗ MISS |
Q3 2022 | Aug 25, 2022 | $-15.35 | $-13.84 | +9.8% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-8.76 | $-20.33 | -132.1% | ✗ MISS |
Q3 2021 | Aug 25, 2021 | — | — | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7
➖ NeutralBenzinga•Dec 5, 2025, 12:55 PM
Neuphoria Therapeutics 13D Filing Shows Lynx1 Capital Management LP Boosts Stake To 16.3% And Submits Revised $4.75-Per-Share Buyout Proposal For Neuphoria Therapeutics
📈 PositiveBenzinga•Dec 2, 2025, 01:40 PM
Neuphoria Initiates Strategic Alternatives Review; Co. Also Confirms Receipt Of Unsolicited Indication Of Interest From Lynx1 Master Fund LP To Acquire All Outstanding Shares It Does Not Already Own For $5.20/Share
📈 PositiveBenzinga•Nov 11, 2025, 12:03 PM
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan To Protect Integrity Of Process; Board Declares Dividend Of One Preferred Share Purchase Right For Each Outstanding Share Of Co
➖ NeutralBenzinga•Oct 27, 2025, 08:53 PM
Neuphoria Therapeutics shares are trading higher. Shareholder Weston Nichols reported purchase of 639,110 shares of Neuphoria Therapeutics at average price of $5.14/share in Form 4 filing on Thursday.
📈 PositiveBenzinga•Oct 24, 2025, 05:54 PM
Neuphoria Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Oct 24, 2025, 01:58 PM
Neuphoria Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 104.94%
📈 PositiveBenzinga•Oct 24, 2025, 01:53 PM
Shareholder Weston Nichols Reported Purchase Of 639,110 Shares Of Neuphoria Therapeutics At Avg Price Of $5.14/Share In Form 4 Filing On Thursday
📈 PositiveBenzinga•Oct 24, 2025, 11:05 AM
Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 20, 2025, 08:40 PM
Trading Halt: Halted at 4:10:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 20, 2025, 08:10 PM
Neuphoria Therapeutics Q4 EPS $(3.98) Misses $(2.08) Estimate, Sales $(13.267K)
📉 NegativeBenzinga•Sep 29, 2025, 09:21 PM
Neuphoria Therapeutics Says On Sept. 10, Nasdaq Provided Co. Notice That It Accepted Plan And Granted Co. Extension Of 180 Calendar Day To Regain Compliance With Listing Rule
📈 PositiveBenzinga•Sep 16, 2025, 01:08 PM
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35
📈 PositiveBenzinga•Sep 11, 2025, 02:30 PM
Neuphoria Therapeutics Completes Target Enrollment Of 332 Patients In Phase 3 AFFIRM-1 Trial Of BNC-210 For Social Anxiety Disorder, With First Data Expected Early Q4 2025
📈 PositiveBenzinga•Sep 4, 2025, 11:21 AM•Also:
HC Wainwright & Co. Reiterates Buy on Neuphoria Therapeutics, Maintains $21 Price Target
📈 PositiveBenzinga•Aug 26, 2025, 02:39 PM
Frequently Asked Questions about NEUP
What is NEUP's current stock price?
Neuphoria Therapeutics Inc. (NEUP) is currently trading at $3.89 per share. The stock has moved +0.00% today.
What is the analyst price target for NEUP?
The average analyst price target for NEUP is $7.00, based on 1 analyst.
What sector is Neuphoria Therapeutics Inc. in?
Neuphoria Therapeutics Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is NEUP's market cap?
Neuphoria Therapeutics Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does NEUP pay dividends?
No, Neuphoria Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALZN
Alzamend Neuro, Inc.
$2.11
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
BMRA
Biomerica, Inc.
$2.31
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$1.02
Mkt Cap: $0.0B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
LUCY
Innovative Eyewear, Inc.
$1.38
Mkt Cap: $0.0B
PFSA
Profusa, Inc. Common Stock
$0.12
Mkt Cap: $0.0B
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
$0.50
Mkt Cap: $0.0B
Explore stocks similar to NEUP for comparison